methods: men with histologically confirmed prostate carcinoma, no recent hormone therapy, a rising serum psa level after radical prostatectomy and/or radiation therapy, and no radiographic evidence of metastases were assigned randomly to receive either oral rosiglitazone (4 mg twice daily) or placebo.